NCT00402025View on ClinicalTrials.gov

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

Talimogene Laherparepvec

Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.

Trial Locations (3)

75246

Mary Crowely Medical Research Center, Dallas

92868

UCI Medical Center, Orange

94115

California Pacific Medical Center, San Francisco

All Listed Sponsors
lead

BioVex Limited

INDUSTRY

NCT00402025 - Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter